Latest News - Valeant NJ

Thursday, February 23, 2017 | Personnel/Company News, Product Launches and Updates, Obagi, Valeant NJ

Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Line

Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s…

Read the full story

Thursday, February 16, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Valeant NJ

FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasis

The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor …

Read the full story

Wednesday, February 01, 2017 | Personnel/Company News, Valeant NJ

Valeant Dermatology to Award $10,000 Scholarships for Undergraduate and Graduate Degrees

Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, will award nine individual scholarships of up to $10,000 through its annual ASPIRE HIGHER Scholarship Program. The scholar…

Read the full story

Tuesday, January 10, 2017 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

L'Oréal Buys CeraVe, AcneFree and AMBI from Valeant

Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in th…

Read the full story

Tuesday, December 13, 2016 | Personnel/Company News, Valeant NJ

Valeant Appoints William D. Humphries As EVP, Dermatology

Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017.  Mr. Humphries will join Valeant's Executive Co…

Read the full story

Thursday, November 17, 2016 | PracticalDermatology.com, Product Launches and Updates, Valeant NJ

New Day Cream, Gel Oil from Cerave

Cerave is expanding their Renewing product line. A new Cerave Skin Renewing Day Cream with Broad Spectrum SPF 30 sunscreen and Skin Renewing Gel Oil now join existing products in this line includin…

Read the full story

Thursday, November 17, 2016 | Business of Medicine, Corporate Lawsuits, Personnel/Company News, Valeant NJ

US Attorney Announces Charges Against Two Executives Tied to Philidor Pharmacy Scheme

The US Attorney’s Office, Southern District of New York has charged two executives in connection with the Philidor Pharmacy scheme that instigated a stock value plunge at Valeant when it was rev…

Read the full story

Thursday, October 06, 2016 | Personnel/Company News, Valeant NJ

Valeant Appoints New Chief Quality Officer

Valeant Pharmaceuticals International, Inc. appointed Louis W. Yu, PhD to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016. Dr. Yu reports to Joseph C. Pa…

Read the full story

Thursday, August 04, 2016 | Healthcare Trends, Personnel/Company News, Valeant NJ

Valeant Dermatology ASPIRE HIGHER Scholarship Program Names Winners

Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC,  announced the winners of its ASPIRE HIGHER Scholarship Program. Nine undergraduate and graduate students were select…

Read the full story

Thursday, July 21, 2016 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

CeraVe: Suncare Products Get Skin Cancer Foundation Seal of Recommendation

Two products from Valeant Consumer Healthcare's CeraVe skincare line have received The Skin Cancer Foundation (SCF) Seal of Recommendation for sunscreens. CeraVe® AM Facial Mois…

Read the full story

Tuesday, July 19, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Psoriasis, Valeant NJ

FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasis

A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committe…

Read the full story

Friday, July 01, 2016 | Personnel/Company News, Leo, Valeant NJ

Valeant Terminates European Licensing Rights for Brodalumab

Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patient…

Read the full story

Thursday, June 16, 2016 | Acquisitions and Mergers, Earnings and Financials, Personnel/Company News, PracticalDermatology.com, Valeant NJ

Changes Afoot at Valeant Pharmaceuticals

Amid reports that its Obagi Medical Products and Solta Medical units  are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fi…

Read the full story

Wednesday, June 15, 2016 | Personnel/Company News, Valeant NJ

Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director

Valeant Pharmaceuticals International, Inc.'s  Board of Directors appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since …

Read the full story

Wednesday, June 08, 2016 | Healthcare Trends, PracticalDermatology.com, Product Launches and Updates, Solta, Valeant NJ

Solta Medical Launches Consumer Campaign to Empower LGBTQ Community

Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s t…

Read the full story
Load More